Taskinen M‐R, Smith U (University of Helsinki, Helsinki, and Sahlgrenska University Hospital, Gothenburg, Sweden). Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998; 244 : 361–70. Diabetes conveys high risk lipid status for cardiovascular disease (CVD). To target the management of diabetic dyslipidaemia requests the understanding of metabolic basis of diabetic dyslipidaemia and its components. Recent progress has opened new information to direct future lipid lowering intervention trials in type 2 diabetic patients. To reduce substantially the risk for CVD aggressive modification of all known risk factors is warranted on the basis of existing data.
No takes yet. Share an insight, caveat, or question.
Taskinen et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: